Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer

@article{Liu2015CombinedNW,
  title={Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer},
  author={Junjun Liu and Xiaosong Chen and Toby M. Ward and Mark Pegram and Kun-wei Shen},
  journal={Tumor Biology},
  year={2015},
  volume={37},
  pages={9825-9835}
}
Women with triple-negative breast cancer have worse prognosis compared to other breast cancer subtypes. Acquired drug resistance remains to be an important reason influencing triple-negative breast cancer treatment efficacy. A prevailing theory postulates that the cancer resistance and recurrence results from a subpopulation of tumor cells with stemness program, which are often insensitive to cytotoxic drugs such as cisplatin. Recent studies suggested that niclosamide, an anti-helminthic drug… CONTINUE READING